Drug Trial Radar · NCT00486811
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Last checked: Nov 19, 2026Latest source record: Oct 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
990
Actual
Start
Jun 2007
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Grünenthal GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- First posted
- Jun 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo (a medication without active substance). In addition the tolerability of CG5503 PR will be assessed. One third of the patients will receive CG5503 and one third will receive placebo. For further comparison one third of the patients will receive oxycodone controlled release (CR) at doses of 20-50 mg twice daily which is an active approved pain medication. Please note that tapentadol ER (Extended Release) and tapentadol PR (Prolonged Release) are identical and used interchangeably. This is due to United States of America and European naming conventions.
Conditions
- Pain
- Knee Osteoarthritis
Interventions
Tapentadol ER (100 to 250 mg twice daily)Drug
50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Matching Placebo (twice daily)Drug
Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
Oxycodone CR (20 to 50 mg twice daily)Drug
10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of the Average Pain Intensity Overall in the 12-week Maintenance Period of the Daily Pain Intensity on an 11-point Numeric Rating Scale (NRS).Time frame: Change from baseline over the 12 week Maintenance Period
Locations
100 sites in 13 countries. Site status is shown where the registry gives one.
Site 043005
Innsbruck, Austria
Site 043006
Mitterdorf, Austria
Site 043002
Salzburg, Austria
Site 043001
Vienna, Austria
Site 043004
Vienna, Austria
Site 043003
Wiener Neustadt, Austria
Site 385003
Karlovac, Croatia
Site 385001
Osijek, Croatia
Site 385004
Sisak, Croatia
Seite 385005
Zagreb, Croatia
Site 385002
Zagreb, Croatia
Site 049002
Berlin, Germany
Site 049008
Berlin, Germany
Site 049010
Berlin, Germany
Site 049003
Dresden, Germany
Site 049004
Frankfurt, Germany
Site 049007
Hamburg, Germany
Site 049001
Leipzig, Germany
Site 049005
Magdeburg, Germany
Site 049009
Schwerin, Germany
Site 049006
Wiesbaden, Germany
Site 036003
Budapest, Hungary
Site 036005
Budapest, Hungary
Site 036006
Budapest, Hungary
Site 036009
Budapest, Hungary
Site 036008
Debrecen, Hungary
Site 036004
Kecskemét, Hungary
Site 036007
Kecskemét, Hungary
Site 036002
Visegrád, Hungary
Site 039002
Chieti, Italy
Site 039003
Milan, Italy
Site 039004
Pavia, Italy
Site 039001
Perugia, Italy
Site 371002
Bauska, Latvia
Site 371004
Riga, Latvia
Site 371005
Riga, Latvia
Site 031008
Eindhoven, Netherlands
Site 031003
Losser, Netherlands
Site 031006
Oude Pekela, Netherlands
Site 031004
s'Hertogenbosch, Netherlands
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.